Bharat Biotech stated the outcomes demonstrated the protecting efficacy of the Covid-19 vaccine in a reside viral problem mannequin.
- IANS Hyderabad
- Last Updated: September 12, 2020, 2:53 PM IST
FOLLOW US ON:
Vaccine maker Bharat Biotech on Friday introduced that the animal trials of its Covid-19 vaccine candidate Covaxin have been profitable.
It stated the outcomes demonstrated the protecting efficacy of the vaccine in a reside viral problem mannequin.
“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” tweeted the Hyderabad-based agency.
It stated the information from the research on primates substantiate the immunogenicity of the vaccine candidate.
According to an in depth assertion hooked up to the tweet, Bharat Biotech developed and assessed the protecting efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) or Covaxin in rhesus macaques (Macaca mulata). Twenty macaques have been divided into 4 teams of 5 animals every.
“One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation,” it stated.
“Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry.”
“To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus,” it added.
The vaccine is being evaluated in Phase-I scientific trials in India.
The vaccine maker early this month obtained approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials.
Bharat Biotech had introduced on June 29 that it efficiently developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The SARS-CoV-2 pressure was remoted in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine candidate has been developed and manufactured in Bharat Biotech’s excessive containment facility situated in Genome Valley, Hyderabad.